Cancer Network | Prostate Cancer
396 FOLLOWERS
Authoritative updates for clinicians on prostate cancer treatment, PSA screening, prostatectomy vs surveillance, chemoprevention, and radiation and proton therapy.
Cancer Network | Prostate Cancer
4d ago
Investigators aim to identify a clinically useful and safe dose of Illuminare-1 for future studies in surgical cancer care ..read more
Cancer Network | Prostate Cancer
3w ago
Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer ..read more
Cancer Network | Prostate Cancer
3w ago
Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy ..read more
Cancer Network | Prostate Cancer
1M ago
Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union ..read more
Cancer Network | Prostate Cancer
2M ago
Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer ..read more
Cancer Network | Prostate Cancer
2M ago
The positive opinion is supported by findings from the phase 3 EMBARK trial assessing enzalutamide in patients with biochemically recurrent prostate cancer ..read more
Cancer Network | Prostate Cancer
2M ago
Results from a post hoc sensitivity analysis of the phase 3 ARASENS trial appear to affirm the primary overall survival analysis findings ..read more
Cancer Network | Prostate Cancer
2M ago
Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer ..read more
Cancer Network | Prostate Cancer
2M ago
Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS ..read more
Cancer Network | Prostate Cancer
2M ago
Leonard G. Gomella, MD, FACS, discusses new clinical trials that are evaluating novel targeted therapy options for those with prostate cancer ..read more